Huge news in APOL1 nephropathy - ten tweets to fill you in here:
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Huge news in APOL1 nephropathy - ten tweets to fill you in here:
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) May 12, 2023
✳️10 tweets #NephJC catch-up ✳️
On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.
Join us here for the recap! pic.twitter.com/LApAHkYn10